02:48 , Jul 29, 2017 |  BioCentury  |  Finance

Potentiator potential

Preclinical data showing how eFT508 could fit into checkpoint inhibitor cocktails helped Effector Therapeutics Inc. snag Pfizer Inc. (NYSE:PFE) as both a development partner and an investor. On July 24, Effector closed a $19.3 million...
14:06 , Jul 24, 2017 |  BC Extra  |  Financial News

Effector raises $38.6M in series C

Cancer company Effector Therapeutics Inc. (San Diego, Calif.) raised $38.6 million in a series C round led by new investor Pfizer Venture Investments. Also participating were new investor Alexandria Venture Investments and existing investors U.S....
07:00 , Sep 18, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer BRAF; eukaryotic translation initiation factor 4A1 (eIF4A1); eIF4F; MEK Studies in patient samples, mice and cell culture suggest disrupting the eIF4F complex could be...
07:00 , Sep 11, 2014 |  BC Innovations  |  Cover Story

Kinase convergence on eIF4F

Researchers in France have shown that resistance to BRAF and MEK inhibitors in melanoma and possibly other cancers can be driven by pathways that converge on the eukaryotic translation initiation factor 4F complex. 1 The...
08:00 , Dec 1, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Infectious disease Burkholderia pseudomallei lethal factor 1 (BPSL1549); eukaryotic translation initiation factor 4A1 (EIF4A1) In vitro and mouse studies identified a toxin from B....
07:00 , Sep 15, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Non-Hodgkin's lymphoma (NHL) Pim-2 (PIM2); eukaryotic translation initiation factor 4A1 (EIF4A1) Patient tissue and mouse studies suggest protein translation inhibitors could help treat chemoresistant PIM2-expressing...